6 Results for "

AR (F876L)

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "AR (F876L)" in MCE Product Catalog:

Cat. No.: HY-136242
CAS No.: 2168525-92-4
Purity:  98.09%
Target:  

Estrogen Receptor/ERR

Research Areas:  

Endocrinology Cancer

UT-34 is a potent, selective, orally bioactive second-generation pan-androgen receptor (AR) antagonist and degrader, with IC50 values of 211.7 nM, 262.4 nM, and 215.7 nM for wild-type AR, F876L-AR, and W741L-AR, respectively. UT-34 binds to the ligand-binding domain (LBD) and functional 1 (AF-1) domain of AR and requires the ubiquitin-proteasome pathway for AR degradation. UT-34 has anti-prostate cancer effects.
loading...
    loading...
Cat. No.: HY-164807
CAS No.: 1489236-55-6
Target:  

HyT Androgen Receptor HSP

Research Areas:  

Cancer

SARD279 is a HyT degrader of androgen receptor (AR). SARD279 binds to AR, recruits HSP70, mediates ubiquitin-dependent proteasomal degradation, and competitively inhibits the transactivation of AR. SARD279 exhibits antiproliferative activity in AR-dependent prostate cancer cells and castration-resistant prostate cancer cells, including those harboring the AR F876L mutation. SARD279 can be used in studies related to prostate cancer and castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-403733C
CAS No.: 2020353-42-6
Target:  

Androgen Receptor

Research Areas:  

Cancer

JJ-450 is a non-competitive antagonist androgen receptor (AR) that inhibits the transcriptional activity of wild-type AR and mutant AR F876L. JJ-450 has an IC50 of approximately 1-10 μM in inhibiting AR transcriptional activity in PC3 cells. It is selective for AR binding and does not compete with androgens for binding to the ligand binding domain (LBD) of AR. JJ-450 inhibits the transcriptional activity of AR and its splice variants (such as AR F876L) by inhibiting AR nuclear translocation and promoting the degradation of unliganded AR in the nucleus. JJ-450 can be used in castration-resistant prostate cancer (CRPC) studies that are resistant to Enzalutamide (MDV3100) (HY-70003) .
loading...
    loading...
Cat. No.: HY-403733A
CAS No.: 1998094-23-7
Target:  

Androgen Receptor

Research Areas:  

Cancer

(-)-JJ-450 is a non-competitive antagonist targeting the androgen receptor (AR). (-)-JJ-450 is more potent than (+)-JJ-450 (HY-403733B) in inhibiting androgen-induced AR activity, and the mechanism of AR inhibition by (+)-JJ-450 is different from that of Enzalutamide (MDV3100) (HY-70003), which may target the ligand binding domain (LBD) of AR. (-)-JJ-450 inhibits the transcriptional activity of wild-type AR and mutant AR F876L by inhibiting AR nuclear translocation and promoting nuclear degradation of unbound AR. (-)-JJ-450 can be used in the study of castration-resistant prostate cancer (CRPC) resistant to Enzalutamide .
loading...
    loading...
Cat. No.: HY-164477
CAS No.: 1431166-12-9
Target:  

Androgen Receptor

Research Areas:  

Cancer

FL442 is an Androgen Receptor (AR) modulator. FL442 exhibits strong inhibitory effects in AR-dependent prostate cancer cells, showing similar inhibitory efficiency to traditional antiandrogen drugs Bicalutamide (HY-14249) and Enzalutamide (HY-70002), while maintaining antiandrogenic activity against the AR mutant F876L, which is highly resistant to Enzalutamide. Pharmacokinetic studies of FL442 in mice reveal a long half-life (8 hours), good targeting (prostate tissue), and metabolic stability, and it effectively inhibits LNCaP tumor growth at low plasma concentrations (30 ng/mL) .
loading...
    loading...
Cat. No.: HY-151266
CAS No.: 2883447-45-6
Target:  

Androgen Receptor

Research Areas:  

Cancer

AR antagonist 4 (Compound 67-b) is an orally active androgen receptor (AR) antagonist with an IC50 of 246.6 nM against wt-AR, and is also an AR degrader with a DC50 of 2.84 μM .
loading...
    loading...